Haisco(SZ:002653) Ge Long Hui A P P·2025-10-09 08:38Core Viewpoint - Haisco (002653.SZ) announced that its subsidiary, Shanghai Haisco Shennuo Pharmaceutical Technology Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for a new drug application for HSK36357 capsules, a novel small molecule drug with independent intellectual property rights [1] Group 1 - HSK36357 is a self-developed drug that has shown significant analgesic effects in non-clinical studies [1] - The drug has demonstrated the ability to enhance skeletal muscle contraction and improve recovery from fatigue in a mouse model of Duchenne Muscular Dystrophy (DMD) [1] - HSK36357 is intended for clinical use in treating muscular dystrophies, including Becker muscular dystrophy and Duchenne muscular dystrophy [1]